Denmark· DK-28107095724
Empagliflozin "Denk"
A empagliflozin product containing empagliflozin, registered in Denmark by Denk Pharma GmbH & Co KG. The same ATC class is registered in 16 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Empagliflozin is registered in 16 of 19 countries.
Countries holding a registration under ATC A10BK03 (empagliflozin), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 9 of them publish a price we can compare per daily dose
Empagliflozin · ATC A10BK03
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of empagliflozin costs, country by country.
Normalised to the WHO defined daily dose (17.5 mg), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Empagliflozin · price per daily dose (17.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$3.80
- IT Italy$2.95
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Empagliflozin
- Manufacturer
- Denk Pharma GmbH & Co KG
- Country
- Denmark (DK)
- ATC code
- A10BK03
- ATC class
- Empagliflozin
- Defined daily dose
- 17.5 mg, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28107095724
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
466 interactions on record for empagliflozin.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Empagliflozin · interactions on record
466 records
- 1 severe
- 425 moderate
- 40 minor
Most severe, free to view
- SucralfateA02BX02moderate
- PapaverineA03AD01moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under A10BK03
Empagliflozin, as other registers publish it.
- DenmarkElemioInnovis Pharma S.A.
- DenmarkElemioInnovis Pharma S.A.
- DenmarkEmpagliflozin "Denk"Denk Pharma GmbH & Co KG
- DenmarkEmpagliflozin "Devatis"Devatis GmbH
- DenmarkEmpagliflozin "Devatis"Devatis GmbH
- DenmarkEmpagliflozin "Krka"KRKA d.d. Novo mesto
- DenmarkEmpagliflozin "Krka"KRKA d.d. Novo mesto
- DenmarkEmpagliflozin "Pharmapath"PharmaPath S.A.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/95318eca-f79c-4d64-b2d3-45cd76a4d084 GET /v1/drugs/95318eca-f79c-4d64-b2d3-45cd76a4d084?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "filmovertrukne tabletter",
"source": "dkma",
"strength": "25 mg",
"auth_role": "RMS",
"dk_drugid": "28107095724",
"substance": "Empagliflozin",
"auth_procedure": "Decentral procedure",
"in_medicinpriser": false,
"registration_date_serial": "45973"
}See everything about empagliflozin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.